ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Vardenafil: Drug information

Vardenafil: Drug information
2024© UpToDate, Inc. and its affiliates and/or licensors. All Rights Reserved.
For additional information see "Vardenafil: Patient drug information"

For abbreviations, symbols, and age group definitions show table
Brand Names: US
  • Levitra [DSC];
  • Staxyn [DSC]
Brand Names: Canada
  • APO-Vardenafil;
  • JAMP-Vardenafil;
  • JAMP-Vardenafil ODT;
  • Levitra [DSC];
  • MYLAN-VARDENAFIL;
  • Staxyn [DSC]
Pharmacologic Category
  • Phosphodiesterase-5 Enzyme Inhibitor
Dosing: Adult

Note: Oral disintegrating tablets should not be used interchangeably with film-coated tablets; patients requiring a dose other than 10 mg should use the film-coated tablets.

Erectile dysfunction

Erectile dysfunction:

Film-coated tablet (Levitra): Oral: 10 mg administered ~60 minutes prior to sexual activity; dosing range: 5 to 20 mg as a single dose (not more than once daily); maximum: 20 mg/day.

Oral disintegrating tablet (Staxyn): Oral: 10 mg administered ~60 minutes prior to sexual activity; maximum: 10 mg/day.

Pulmonary arterial hypertension

Pulmonary arterial hypertension (off-label use):

Note: Consult a pulmonary arterial hypertension specialist for all management decisions; choice of therapy is dependent on etiology, risk stratification, and cardiopulmonary comorbidities. Vardenafil is contraindicated in patients taking riociguat due to potentially severe hypotension (Ref).

Oral: 5 mg once daily for 4 weeks, then increase to target dose of 5 mg twice daily if tolerated (Ref).

Raynaud phenomenon

Raynaud phenomenon (off-label use): Oral: 10 mg twice daily (Ref).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult Drug Interactions database for more information.

Dosing: Kidney Impairment: Adult

Mild, moderate, or severe impairment: No dosage adjustment necessary.

Hemodialysis: Use is not recommended.

Dosing: Hepatic Impairment: Adult

Erectile dysfunction:

Mild impairment (Child-Pugh class A): No dosage adjustment necessary.

Moderate impairment (Child-Pugh class B):

Film-coated tablet (Levitra): Oral: Initial: 5 mg administered ~60 minutes prior to sexual activity (maximum: 10 mg/day).

Oral disintegrating tablet (Staxyn): Use is not recommended.

Severe impairment (Child-Pugh class C): Use is not recommended (has not been studied).

Dosing: Older Adult

Erectile dysfunction: Film-coated tablet (Levitra): Oral: Consider a lower initial dose of 5 mg administered ~60 minutes prior to sexual activity.

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults.

>10%:

Cardiovascular: Flushing (8% to 11%)

Nervous system: Headache (14% to 15%)

1% to 10%:

Cardiovascular: Acute myocardial infarction (<2%), angina pectoris (<2%), chest pain (<2%), hypotension (<2%), increased serum creatine kinase (2%), palpitations (<2%), syncope (<2%), tachycardia (<2%), ventricular tachyarrhythmia (<2%)

Dermatologic: Erythema of skin (<2%), skin rash (<2%)

Gastrointestinal: Abdominal pain (<2%), diarrhea (<2%), dyspepsia (3% to 4%), gastritis (<2%), gastroesophageal reflux disease (<2%), gastrointestinal pain (<2%), nausea (2%), vomiting (<2%), xerostomia (<2%)

Genitourinary: Frequent erections (<2%), priapism (<2%)

Hepatic: Increased serum transaminases (<2%)

Hypersensitivity: Allergic angioedema (<2%), angioedema (<2%), hypersensitivity reaction (<2%)

Nervous system: Amnesia (<2%), dizziness (2%), drowsiness (<2%), dysesthesia (<2%), hypertonia (<2%), malaise (<2%), paresthesia (<2%), seizure (<2%), sleep disturbance (<2%), vertigo (<2%)

Neuromuscular & skeletal: Back pain (2%), increased creatine phosphokinase in blood specimen (<2%), muscle cramps (<2%), myalgia (<2%)

Ophthalmic: Conjunctivitis (<2%), eye discomfort (<2%), eye pain (<2%), increased intraocular pressure (<2%), ocular hyperemia (<2%), photophobia (<2%), vision color changes (<2%), visual disturbance (<2%)

Otic: Tinnitus (<2%)

Respiratory: Dyspnea (<2%), flu-like symptoms (3%), nasal congestion (3%), paranasal sinus congestion (<2%), rhinitis (9%), sinusitis (3%)

Postmarketing:

Cardiovascular: Atrial fibrillation (Veloso 2005)

Dermatologic: Basal cell carcinoma (Loeb 2015), malignant melanoma (Loeb 2015), Stevens-Johnson syndrome (Grafanaki 2022), toxic epidermal necrolysis (Grafanaki 2022)

Nervous system: Recurrent seizures, temporary amnesia (global)

Ophthalmic: Anterior ischemic optic neuropathy (nonarteritic; NAION), decreased visual acuity, retinal vein occlusion, vision loss (temporary vision loss, permanent vision loss), visual field defect

Otic: Auditory impairment (including decreased hearing, hearing loss, sensorineural hearing loss) (Barreto 2013)

Contraindications

Coadministration with nitrates (either regularly and/or intermittently), nitric oxide donors, or guanylate cyclase stimulators (eg, riociguat).

Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Canadian labeling: Additional contraindications (not in US labeling): Hypersensitivity to vardenafil or any component of the formulation; concomitant use with cobicistat, indinavir, ritonavir, saquinavir, atazanavir, ketoconazole or itraconazole (Levitra, Staxyn), and erythromycin or clarithromycin (Staxyn); prior episode of non-arteritic anterior ischemic optic neuropathy.

Warnings/Precautions

Concerns related to adverse effects:

• Color discrimination: May cause dose-related impairment of visual color discrimination (blue/green).

• Hearing loss: Sudden decrease or loss of hearing has been reported rarely; hearing changes may be accompanied by tinnitus and dizziness. A direct relationship between therapy and hearing loss has not been determined.

• Hypotension: Decreases in blood pressure may occur due to vasodilator effects. Use with caution in patients with left ventricular outflow obstruction (aortic stenosis or hypertrophic cardiomyopathy with outflow tract obstruction); may be more sensitive to hypotensive actions. Concurrent use with alpha-adrenergic antagonist therapy may cause symptomatic hypotension; ensure hemodynamic stability prior to initiating film-coated tablets and use the lowest possible dose; do not initiate oral disintegrating tablet in patients taking alpha-adrenergic antagonists. Avoid or limit concurrent substantial ethanol consumption as this may increase the risk of symptomatic hypotension.

• Priapism: Painful erection >6 hours in duration has been reported (rarely). Instruct patients to seek immediate medical attention if erection persists >4 hours. Use with caution in patients who have conditions which may predispose them to priapism (sickle cell anemia, multiple myeloma, leukemia).

• Vision loss: Vision loss may occur rarely and be a sign of non-arteritic anterior ischemic optic neuropathy (NAION). Instruct patients to seek medical assistance for sudden loss of vision in one or both eyes. Patients who have already experienced NAION are at an increased risk of recurrence. Other risk factors for NAION include low cup-to-disc ratio (“crowded disc”), coronary artery disease, diabetes, hypertension, hyperlipidemia, smoking, and age >50 years; use with caution and only when the benefits outweigh the risks in these patients. Safety and efficacy were not studied in patients with known degenerative retinal disorders (eg, retinitis pigmentosa); use is not recommended.

Disease-related concerns:

• Anatomical penis deformation: Use with caution in patients with anatomical deformation of the penis (angulation, cavernosal fibrosis, or Peyronie disease).

• Bleeding disorders: Use with caution in patients with bleeding disorders; safety and efficacy have not been established.

• Cardiovascular disease: Use is not recommended in patients with hypotension (resting systolic BP <90 mm Hg); uncontrolled hypertension (>170/100 mm Hg); unstable angina or angina during intercourse; life-threatening arrhythmias, stroke, or MI within the last 6 months; cardiac failure or coronary artery disease causing unstable angina. Safety and efficacy have not been studied in these patients. Use caution in patients with left ventricular outflow obstruction (eg, aortic stenosis, hypertrophic cardiomyopathy with outflow tract obstruction). There is a degree of cardiac risk associated with sexual activity; therefore, physicians may wish to consider the cardiovascular status of their patients prior to initiating any treatment for erectile dysfunction.

• Congenital or acquired QT prolongation: Not recommended for use in patients with congenital or acquired (ie, medication induced) QT prolongation.

• Hepatic impairment: Use with caution in patients with moderate hepatic impairment (Child-Pugh class B); dosage adjustment is needed. Safety and efficacy have not been studied in patients with severe hepatic impairment (Child-Pugh class C); therefore, use in these patients is not recommended. Per the manufacturer, the oral disintegrating tablet should not be used in patients with moderate to severe hepatic impairment.

• Peptic ulcer disease: Use with caution in patients with active peptic ulcer disease; safety and efficacy have not been established.

• Renal impairment: Safety and efficacy have not been studied in patients with end-stage renal disease requiring dialysis; therefore, use in these patients is not recommended.

Concurrent drug therapy issues:

• Nitrates: Concomitant use with all forms of nitrates is contraindicated. If nitrate administration is medically necessary, it is not known when nitrates can be safely administered following the use of vardenafil; however, when a 20 mg (film-coated tablet) was administered 24 hours prior to a 0.4 mg sublingual dose of nitroglycerin, no changes in blood pressure or heart rate were detected.

Special populations:

• Older adult: Use with caution in older adults; dosage reduction may be necessary.

Dosage form specific issues:

• Phenylalanine: Some products may contain phenylalanine.

• Sorbitol: Some products may contain sorbitol; do not use in patients with fructose intolerance.

Other warnings/precautions:

• Appropriate use: Potential underlying causes of erectile dysfunction should be evaluated prior to treatment.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Tablet, Oral:

Levitra: 10 mg [DSC], 20 mg [DSC]

Generic: 2.5 mg, 5 mg, 10 mg, 20 mg

Tablet Disintegrating, Oral:

Staxyn: 10 mg [DSC] [contains aspartame]

Generic: 10 mg

Generic Equivalent Available: US

Yes

Pricing: US

Tablet, orally-disintegrating (Vardenafil HCl Oral)

10 mg (per each): $36.18

Tablets (Vardenafil HCl Oral)

2.5 mg (per each): $55.56 - $58.72

5 mg (per each): $55.56 - $58.72

10 mg (per each): $55.56 - $58.72

20 mg (per each): $55.56 - $58.72

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Tablet, Oral:

Levitra: 5 mg [DSC], 10 mg [DSC], 20 mg [DSC]

Generic: 5 mg, 10 mg, 20 mg

Tablet Disintegrating, Oral:

Staxyn: 10 mg [DSC] [contains aspartame]

Generic: 10 mg

Administration: Adult

May be administered with or without food, approximately 60 minutes prior to sexual activity.

Oral disintegrating tablet should not be removed from blister pack until administered. Using dry hands, place immediately on tongue. Tablet will dissolve rapidly; do not take with liquid. Do not crush, split, or chew.

Use: Labeled Indications

Erectile dysfunction: Treatment of erectile dysfunction.

Use: Off-Label: Adult

Pulmonary arterial hypertension; Raynaud phenomenon

Medication Safety Issues
Sound-alike/look-alike issues:

Vardenafil may be confused with sildenafil, tadalafil

Levitra may be confused with Kaletra, Lexiva

Metabolism/Transport Effects

Substrate of CYP3A4 (major); Note: Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program by clicking on the “Launch drug interactions program” link above.

Alcohol (Ethyl): May enhance the hypotensive effect of Phosphodiesterase 5 Inhibitors. Risk C: Monitor therapy

Alpha1-Blockers (Nonselective): Phosphodiesterase 5 Inhibitors may enhance the hypotensive effect of Alpha1-Blockers (Nonselective). Management: Ensure patient is stable on one agent prior to initiating the other, and always initiate combination using the lowest possible dose of the drug being added. When tadalafil is used for treatment of BPH, concurrent alpha 1-blockers are not recommended. Risk D: Consider therapy modification

Alpha1-Blockers (Uroselective): May enhance the hypotensive effect of Phosphodiesterase 5 Inhibitors. Risk C: Monitor therapy

Alprostadil: Phosphodiesterase 5 Inhibitors may enhance the adverse/toxic effect of Alprostadil. Risk X: Avoid combination

Amyl Nitrite: Phosphodiesterase 5 Inhibitors may enhance the vasodilatory effect of Amyl Nitrite. Risk X: Avoid combination

Blood Pressure Lowering Agents: Phosphodiesterase 5 Inhibitors may enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Bosentan: May decrease the serum concentration of Phosphodiesterase 5 Inhibitors. Phosphodiesterase 5 Inhibitors may increase the serum concentration of Bosentan. Risk C: Monitor therapy

Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk C: Monitor therapy

Cobicistat: May increase the serum concentration of Vardenafil. Management: Limit the dose of vardenafil tablets to a single 2.5 mg dose within a 72-hour period if combined with cobicistat. Avoid concomitant use of vardenafil orally disintegrating tablets and cobicistat. Combined use is contraindicated outside of the US. Risk D: Consider therapy modification

CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Vardenafil. Management: Limit Levitra (vardenafil) dose to a single 5 mg dose within a 24-hour period if combined with moderate CYP3A4 inhibitors. Avoid concomitant use of Staxyn (vardenafil) and moderate CYP3A4 inhibitors. Combined use is contraindicated outside of the US. Risk D: Consider therapy modification

CYP3A4 Inhibitors (Strong): May increase the serum concentration of Vardenafil. Management: Limit Levitra (vardenafil) dose to a single 2.5 mg dose within a 24-hour period if combined with strong CYP3A4 inhibitors. Avoid concomitant use of Staxyn (vardenafil) and strong CYP3A4 inhibitors. Combined use is contraindicated outside of the US. Risk D: Consider therapy modification

Dapoxetine: May enhance the orthostatic hypotensive effect of Phosphodiesterase 5 Inhibitors. Risk X: Avoid combination

Etravirine: May decrease the serum concentration of Phosphodiesterase 5 Inhibitors. Risk C: Monitor therapy

Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk X: Avoid combination

Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Consider avoiding this combination if possible. If required, monitor patients closely for increased adverse effects of the CYP3A4 substrate. Risk D: Consider therapy modification

Grapefruit Juice: May increase the serum concentration of Vardenafil. Management: Avoid grapefruit juice consumption whenever possible. Limit Levitra (vardenafil) dose to a single 5 mg dose within a 24-hour period if combined grapefruit juice. Strictly avoid concomitant use of Staxyn (vardenafil) and grapefruit juice. Risk D: Consider therapy modification

Haloperidol: QT-prolonging Agents (Indeterminate Risk - Avoid) may enhance the QTc-prolonging effect of Haloperidol. Risk C: Monitor therapy

Itraconazole: May increase the serum concentration of Vardenafil. Management: Limit Levitra (vardenafil) dose to 5 mg per 24 hours with itraconazole 200 mg/day and 2.5 mg per 24 hours with itraconazole 400 mg/day. Avoid concomitant use of Staxyn (vardenafil) and itraconazole. Combined use is contraindicated outside of the US. Risk D: Consider therapy modification

Ketoconazole (Systemic): May increase the serum concentration of Vardenafil. Management: Limit Levitra (vardenafil) dose to 5 mg per 24 hours with ketoconazole 200 mg/day and 2.5 mg per 24 hours with ketoconazole 400 mg/day. Avoid concomitant use of Staxyn (vardenafil) and ketoconazole. Combined use is contraindicated outside of the US. Risk D: Consider therapy modification

Lorcaserin (Withdrawn From US Market): May enhance the adverse/toxic effect of Phosphodiesterase 5 Inhibitors. Specifically, the risk of developing priapism may be increased. Risk C: Monitor therapy

Molsidomine: May enhance the hypotensive effect of Phosphodiesterase 5 Inhibitors. Risk X: Avoid combination

Nirmatrelvir and Ritonavir: May increase the serum concentration of Vardenafil. Management: Limit the dose of vardenafil tablets to a single 2.5 mg dose within a 72-hour period if combined with nirmatrelvir/ritonavir. Avoid concomitant use of vardenafil orally disintegrating tablets and nirmatrelvir/ritonavir. Risk D: Consider therapy modification

Nitroprusside: Phosphodiesterase 5 Inhibitors may enhance the hypotensive effect of Nitroprusside. Risk X: Avoid combination

Phosphodiesterase 5 Inhibitors: May enhance the adverse/toxic effect of other Phosphodiesterase 5 Inhibitors. Risk X: Avoid combination

QT-prolonging Agents (Highest Risk): QT-prolonging Agents (Indeterminate Risk - Avoid) may enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk C: Monitor therapy

Riociguat: Phosphodiesterase 5 Inhibitors may enhance the hypotensive effect of Riociguat. Risk X: Avoid combination

Ritonavir: May increase the serum concentration of Vardenafil. Management: Limit the dose of vardenafil tablets to a single 2.5 mg dose within a 72-hour period if combined with ritonavir. Avoid concomitant use of vardenafil orally disintegrating tablets and ritonavir. Combined use is contraindicated outside of the US. Risk D: Consider therapy modification

Sapropterin: May enhance the hypotensive effect of Phosphodiesterase 5 Inhibitors. Risk C: Monitor therapy

Simeprevir: May increase the serum concentration of Phosphodiesterase 5 Inhibitors. Risk C: Monitor therapy

Vasodilators (Organic Nitrates): Phosphodiesterase 5 Inhibitors may enhance the vasodilatory effect of Vasodilators (Organic Nitrates). Risk X: Avoid combination

Vericiguat: May enhance the hypotensive effect of Phosphodiesterase 5 Inhibitors. Risk X: Avoid combination

Food Interactions

High-fat meals decrease maximum serum concentration 18% to 50%. Serum concentrations/toxicity may be increased with grapefruit juice. Management: Do not take with a high-fat meal. Monitor for increased effects/toxicity with concomitant grapefruit consumption.

Reproductive Considerations

No effects on sperm motility or morphology were observed in healthy males; increased sperm count and motility were observed in patients with oligozoospermia (Drobnis 2017).

Pregnancy Considerations

Adverse events were not observed in animal reproduction studies.

Vardenafil has been evaluated for the treatment of pulmonary arterial hypertension (PAH) (Jing 2011). Untreated PAH in pregnancy increases the risk for heart failure, stroke, preterm delivery, and maternal/fetal death. Patients with PAH are encouraged to avoid becoming pregnant (ACCP [Klinger 2019]; Hemnes 2015). If treatment with a phosphodiesterase-5 enzyme inhibitor is needed for the treatment of PAH during pregnancy, agents other than vardenafil are suggested (ESC [Regitz-Zagrosek 2018], Hemnes 2015).

Breastfeeding Considerations

It is not known if vardenafil is present in breast milk.

Dietary Considerations

Some products may contain phenylalanine. Some products may contain sorbitol; do not use in patients with fructose intolerance.

Monitoring Parameters

Monitor BP, heart rate, signs/symptoms of orthostasis; visual impairment (eg, vision loss, cyanopsia); hearing impairment; prolonged erection and/or priapism.

Mechanism of Action

Does not directly cause penile erections, but affects the response to sexual stimulation. The physiologic mechanism of erection of the penis involves release of nitric oxide (NO) in the corpus cavernosum during sexual stimulation. NO then activates the enzyme guanylate cyclase, which results in increased levels of cyclic guanosine monophosphate (cGMP), producing smooth muscle relaxation and inflow of blood to the corpus cavernosum. Vardenafil enhances the effect of NO by inhibiting phosphodiesterase type 5 (PDE-5), which is responsible for degradation of cGMP in the corpus cavernosum; when sexual stimulation causes local release of NO, inhibition of PDE-5 by vardenafil causes increased levels of cGMP in the corpus cavernosum, resulting in smooth muscle relaxation and inflow of blood to the corpus cavernosum; at recommended doses, it has no effect in the absence of sexual stimulation.

Pharmacokinetics (Adult Data Unless Noted)

Onset of action: ~60 minutes

Absorption: Rapid

Distribution: Vd: 208 L

Protein binding: ~95% (parent drug and metabolite)

Metabolism: Hepatic via CYP3A4 (major), CYP2C and 3A5 (minor); forms metabolite (active)

Bioavailability: ~15%

Film-coated tablet: Elderly (≥65 years): AUC increased by 52%; Hepatic impairment (moderate, Child-Pugh class B): AUC increased by 160%

Oral disintegrating tablet: Elderly (≥65 years): AUC increased by 21% more compared to film-coated tablet. When administered with water, AUC decreases by 29%.

Half-life elimination: Terminal: Vardenafil and metabolite: 4 to 6 hours

Time to peak, plasma: 0.5 to 2 hours

Excretion: Feces (~91% to 95% as metabolites); urine (~2% to 6%)

Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)

Altered kidney function: The AUC was 20% to 30% higher in moderate (CrCl 30 to 50 mL/minute) and severe (CrCl <30 mL/minute) renal impairment.

Hepatic function impairment: In patients with mild hepatic impairment (Child-Pugh class A), Cmax and AUC increased by 22% and 17%, respectively. In patients with moderate hepatic impairment (Child-Pugh class B), Cmax and AUC increased by 130% and 160%, respectively.

Older adult: In men ≥65 years of age, the Cmax and AUC are increased 34% and 52%, respectively, for Levitra and by 21% and 39%, respectively, for Staxyn compared with men <45 years.

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (AE) United Arab Emirates: Levitra | Lexta | X pert;
  • (AT) Austria: Levitra | Vardenafil 1a pharma | Vardenafil rivopharm | Vardenafil sandoz | Vardenafil stada | Vardenaristo | Vivanza;
  • (AU) Australia: Levitra;
  • (BD) Bangladesh: Vardamate;
  • (BE) Belgium: Levitra | Vardenafil krka | Vardenafil sandoz | Vivanza;
  • (BG) Bulgaria: Levitra | Vardenafil;
  • (BR) Brazil: Levitra | Vivanza;
  • (CH) Switzerland: Levitra | Vardenafil mepha | Vivanza;
  • (CL) Chile: Levitra;
  • (CN) China: Levitra;
  • (CO) Colombia: Levitra | Xoxaxin;
  • (CZ) Czech Republic: Levitra;
  • (DE) Germany: Levitra | Vardegin | Vardenafil 1a pharma | Vardenafil abz | Vardenafil holsten | Vardenafil neuraxpharm | Vardenafil zentiva | Vardenaristo | Vivanza;
  • (DO) Dominican Republic: Levitra;
  • (EC) Ecuador: Levitra | Levitra odt | Varfil;
  • (EE) Estonia: Levitra | Vardegin | Vardenafil actavis | Vardenafil sandoz | Vardenafil sanoswiss;
  • (EG) Egypt: Dispatigra | Erectnapofil | Farorecta | Levitra | Powerecta | Rapidoverd | Romantigra | Rowadinafil | Solvetra | Vardarict | Vardatrin | Vardection | Vardena | Vardirose | Varnova | Verdenodeb | Vigafil | Vivanza | Westrecta;
  • (ES) Spain: Levatik | Levitra | Sarilen | Vardenafilo | Vardenafilo aristo | Vardenafilo aurovitas | Vardenafilo cinfa | Vardenafilo flas stadagen | Vardenafilo krka | Vardenafilo pensa | Vardenafilo qualigen | Vardenafilo ratiopharm | Vardenafilo stada | Vardenafilo tecnigen | Vardenafilo teva | Vivanza;
  • (FI) Finland: Levitra | Vardenafil accord | Vardenafil krka | Vardenafil stada;
  • (FR) France: Levitra | Vardenafil accord | Vardenafil biogaran | Vardenafil krka | Vardenafil mylan | Vardenafil sandoz;
  • (GB) United Kingdom: Levitra | Vardenafil | Vardenafil accord | Vardenafil aristo | Vardenafil mylan | Vardenafil zentiva;
  • (GR) Greece: Levitra | Vivanza;
  • (HK) Hong Kong: Levitra;
  • (HR) Croatia: Levitra;
  • (HU) Hungary: Levitra | Vardenafil rivopharm;
  • (ID) Indonesia: Levitra;
  • (IE) Ireland: Levitra;
  • (IL) Israel: Levitra;
  • (IN) India: Edafil | Levifil | Valif | Varimax | Vilitra;
  • (IQ) Iraq: Horse man;
  • (IT) Italy: Elutatis | Levitra | Vardenafil | Vardenafil accord | Vardenafil aristo | Vardenafil aristo pharma | Vardenafil doc | Vardenafil eg | Vardenafil krka | Vardenafil mylan | Vardenafil pensa | Vardenafil sandoz | Vardenafil tecnigen | Vardenafil zentiva | Vivanza;
  • (JO) Jordan: Levitra;
  • (JP) Japan: Levitra | Vardenafil fci;
  • (KE) Kenya: Levitra | Varnil;
  • (KR) Korea, Republic of: Levitra | Yaila;
  • (KW) Kuwait: Levitra | X pert;
  • (LB) Lebanon: Levitra;
  • (LT) Lithuania: Levitra | Vardenafil sanoswiss;
  • (LU) Luxembourg: Levitra | Vivanza;
  • (LV) Latvia: Levitra | Vardenafil actavis | Vardenafil sandoz | Vardenafil sanoswiss | Viavardis;
  • (MA) Morocco: Levitra;
  • (MX) Mexico: Levitra;
  • (MY) Malaysia: Levitra;
  • (NL) Netherlands: Levitra | Vardenafil accord | Vardenafil teva;
  • (NO) Norway: Levitra | Vardenafil aristo | Vardenafil krka;
  • (NZ) New Zealand: Levitra | Vardenafil;
  • (PE) Peru: Levitra;
  • (PH) Philippines: Levitra | Vardenafil;
  • (PL) Poland: Levitra | Vardenafil accord | Viavardis;
  • (PR) Puerto Rico: Levitra | Staxyn;
  • (PT) Portugal: Levitra | Vardenafil | Vardenafil aristo | Vardenafil ciclum | Vardenafil generis | Vardenafil krka | Vardenafil tolife;
  • (PY) Paraguay: Eroxil | Novopramil | Vardemax | Vardenafil eticos;
  • (QA) Qatar: Levitra | Levitra ODT | X-Pert | X-Pert D;
  • (RO) Romania: Levitra;
  • (RU) Russian Federation: Levitra | Vardenafil;
  • (SA) Saudi Arabia: Devarin | Erevard | Levitra;
  • (SE) Sweden: Levitra | Vardenafil accord | Vardenafil aristo | Vardenafil krka | Vardenafil sanoswi | Vardenafil stada;
  • (SG) Singapore: Levitra;
  • (SI) Slovenia: Levitra | Viavardis;
  • (SK) Slovakia: Levitra;
  • (TH) Thailand: Levitra;
  • (TR) Turkey: Levitra | Lovitrec;
  • (TW) Taiwan: Levitra | Verticord;
  • (UA) Ukraine: Levitra;
  • (UG) Uganda: Levitra;
  • (VE) Venezuela, Bolivarian Republic of: Levitra;
  • (VN) Viet Nam: Levina | Levivina | Varafil;
  • (ZA) South Africa: Levitra | Varfydo fc
  1. Anderson JL, Adams CD, Antman EM, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127(23):e663-e828. doi:10.1161/CIR.0b013e31828478ac [PubMed 23630129]
  2. Barreto MA, Bahmad F Jr. Phosphodiesterase type 5 inhibitors and sudden sensorineural hearing loss. Braz J Otorhinolaryngol. 2013;79(6):727-733. doi:10.5935/1808-8694.20130133 [PubMed 24474485]
  3. Caglayan E, Axmann S, Hellmich M, Moinzadeh P, Rosenkranz S. Vardenafil for the treatment of Raynaud phenomenon: a randomized, double-blind, placebo-controlled crossover study. Arch Intern Med. 2012;172(15):1182-1184. [PubMed 22710940]
  4. Caglayan E, Huntgeburth M, Karasch T, et al. Phosphodiesterase type 5 inhibition is a novel therapeutic option in Raynaud disease. Arch Intern Med. 2006;166(2):231-233. [PubMed 16432094]
  5. Cheitlin MD, Hutter AM Jr, Brindis RG, et al. Use of Sildenafil (Viagra®) in Patients With Cardiovascular Disease. J Am Coll Cardiol. 1999;33(1):273-282. [PubMed 9935041]
  6. Drobnis EZ, Nangia AK. Phosphodiesterase inhibitors (PDE inhibitors) and male reproduction. Adv Exp Med Biol. 2017;1034:29-38. doi:10.1007/978-3-319-69535-8_5 [PubMed 29256125]
  7. Grafanaki K, Lygeros S, Vryzaki EM, Georgiou S. Rare vardenafil-associated Stevens-Johnson syndrome: toxic epidermal necrolysis. BMJ Case Rep. 2022;15(2):e249013. doi:10.1136/bcr-2022-249013 [PubMed 35228254]
  8. Hemnes AR, Kiely DG, Cockrill BA, et al. Statement on pregnancy in pulmonary hypertension from the Pulmonary Vascular Research Institute. Pulm Circ. 2015;5(3):435-465. doi:10.1086/682230 [PubMed 26401246]
  9. Humbert M, Kovacs G, Hoeper MM, et al; ESC/ERS Scientific Document Group. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022;43(38):3618-3731. doi:10.1093/eurheartj/ehac237 [PubMed 36017548]
  10. Jackson G, Rosen RC, Kloner RA, et al. The Second Princeton Consensus on Sexual Dysfunction and Cardiac Risk: New Guidelines for Sexual Medicine. J Sex Med. 2006;3(1):28-36. [PubMed 16409215]
  11. Jing ZC, Yu ZX, Shen JY, et al; Efficacy and Safety of Vardenafil in the Treatment of Pulmonary Arterial Hypertension (EVALUATION) Study Group. Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study. Am J Respir Crit Care Med. 2011;183(12):1723-1729. doi:10.1164/rccm.201101-0093OC [PubMed 21471085]
  12. Klinger JR, Elliott CG, Levine DJ, et al. Therapy for pulmonary arterial hypertension in adults: update of the CHEST guideline and expert panel report. Chest. 2019;155(3):565-586. doi:10.1016/j.chest.2018.11.030 [PubMed 30660783]
  13. Kowal-Bielecka O, Fransen J, Avouac J, et al; EUSTAR Coauthors. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017;76(8):1327-1339. doi:10.1136/annrheumdis-2016-209909 [PubMed 27941129]
  14. Levitra (vardenafil) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc; March 2023.
  15. Levitra (vardenafil) [product monograph]. Mississauga, Ontario, Canada: Bayer Inc; February 2020.
  16. Loeb S, Folkvaljon Y, Lambe M, et al. Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma. JAMA. 2015;313(24):2449-2455. [PubMed 26103029]
  17. McVary KT. Clinical Practice. Erectile Dysfunction. N Engl J Med. 2007;357(24):2472-2481. [PubMed 18077811]
  18. Nehra A, Jackson G, Miner M, et al. The Princeton III Consensus recommendations for the management of erectile dysfunction and cardiovascular disease. Mayo Clin Proc. 2012;87(8):766-778. doi:10.1016/j.mayocp.2012.06.015 [PubMed 22862865] 10.1016/j.mayocp.2012.06.015
  19. O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127(4):e362-e425. [PubMed 23247304]
  20. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J. 2018;39(34):3165-3241. doi:10.1093/eurheartj/ehy340 [PubMed 30165544]
  21. Roustit M, Blaise S, Allanore Y, Carpentier PH, Caglayan E, Cracowski JL. Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud's phenomenon: systematic review and meta-analysis of randomized trials. Ann Rheum Dis. 2013;72(10):1696-1699. [PubMed 23426043]
  22. Staxyn (vardenafil) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; April 2023.
  23. Staxyn (vardenafil) [product monograph]. Mississauga, Ontario, Canada: Bayer Inc; February 2020.
  24. Veloso HH, de Paola AA. Atrial fibrillation after vardenafil therapy. Emerg Med J. 2005;22(11):823. doi:10.1136/emj.2004.015982 [PubMed 16244351]
Topic 10172 Version 320.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟